News from grünenthal group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 12, 2021, 08:00 ET Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech...

Mar 01, 2021, 07:12 ET Grünenthal Germany is a Great Place to Work®

Grünenthal Germany is now certified as a Great Place to Work® and a Great Start! company for apprentices. The company was awarded these two...

Feb 12, 2021, 07:37 ET Grünenthal successfully extends its term loan bank facilities

Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader ...

Feb 10, 2021, 02:00 ET Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)

Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total...

Jan 12, 2021, 03:00 ET Florian Dieckmann new VP Global Communications at Grünenthal

Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štěpán Kráčala, who...

Dec 16, 2020, 05:28 ET Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide ...

Dec 01, 2020, 03:58 ET Grünenthal agrees to acquire European rights to CRESTOR™ (rosuvastatin) from AstraZeneca

Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights...

Jul 21, 2020, 11:38 ET Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA®...

Feb 04, 2020, 04:42 ET Grünenthal Invests in e-mobility at Headquarters in Aachen

Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of...

Jan 29, 2020, 06:41 ET Grünenthal Expands Its Network Through Innovation Hub in Boston

Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with...

Dec 18, 2019, 09:03 ET Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the Grünenthal Group, announced today that the supplemental New Drug...

Dec 10, 2019, 06:46 ET Jan Adams Appointed Chief Scientific Officer for Grünenthal

Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective ...

May 02, 2019, 08:52 ET Five Young Scientists Win EFIC-Grünenthal Grant 2018

The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...

Jan 22, 2019, 05:25 ET Grünenthal: Fabian Raschke Appointed Chief Financial Officer (CFO)

Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...

Dec 14, 2018, 02:00 ET Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety

Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...

Nov 14, 2018, 03:27 ET Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...

Nov 05, 2018, 07:04 ET Grünenthal Acquires Global Rights for Qutenza®

Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for ...

Oct 30, 2018, 04:34 ET Grünenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo

Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management...

Jun 18, 2018, 07:18 ET EFIC: Fresh Ideas in Pain Research

Creative approaches to research by young scientists provide opportunity for new and challenging thinking to benefit patients who suffer from pain. To ...

Jun 12, 2018, 07:25 ET Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate...

Feb 01, 2018, 06:11 ET Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP)...

Jan 23, 2018, 06:50 ET Grünenthal distribuirá, promocionará y venderá productos de Salud Femenina de MSD en varios países de Latinoamérica

Grünenthal ha anunciado hoy que ha firmado un acuerdo con MSD (nombre comercial de Merck & Co., Inc., Kenilworth, N.J., EE.UU.) para la distribución, ...

Jan 23, 2018, 05:58 ET Grünenthal to Distribute, Promote, and Sell MSD's Women's Health Products in Several Countries in Latin America

Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for...

Jan 15, 2018, 12:00 ET Grünenthal and Mundipharma Enter Commercial Partnership in China

Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market ...

Dec 05, 2017, 01:06 ET New Partnership for the Commercialization of Nucynta® in the U.S. Territory

The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc.,...